A pilot phase II study to determine the safety and efficacy of the combination of ONTAK (DAB389IL-2) [denileukin diftitox] with CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] in peripheral T-cell lymphoma

Trial Profile

A pilot phase II study to determine the safety and efficacy of the combination of ONTAK (DAB389IL-2) [denileukin diftitox] with CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] in peripheral T-cell lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2015

At a glance

  • Drugs Denileukin diftitox (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record (NCT00337987).
    • 09 Feb 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record (NCT00337987).
    • 01 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top